P. Sidharta

发表

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

L. Rubin, J. Dingemanse, P. Sidharta, 2014, Expert opinion on drug safety.

Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions

R. de Kanter, A. Treiber, P. Sidharta, 2016, Clinical Pharmacokinetics.

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

J. Dingemanse, P. Sidharta, J. Atsmon, 2013, Clinical Pharmacokinetics.

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data

H. E. Meyer zu Schwabedissen, J. Dingemanse, P. Sidharta, 2022, Frontiers in Pharmacology.

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

J. Dingemanse, P. Sidharta, I. Ulč, 2014, Journal of clinical pharmacology.

Investigation of the Effect of Macitentan on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

J. Dingemanse, P. Sidharta, H. Dietrich, 2014, Clinical Drug Investigation.

Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

S. Krähenbühl, J. Dingemanse, P. Sidharta, 2015, Expert opinion on drug metabolism & toxicology.

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.

M. Wolzt, J. Dingemanse, P. Sidharta, 2014, British journal of clinical pharmacology.

Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex

J. Dingemanse, P. Sidharta, J. Marjason, 2013, Pharmacology.

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

Markus S. Mueller, B. Darpo, J. Dingemanse, 2020, Orphanet Journal of Rare Diseases.

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

G. Hopfgartner, M. Seiberling, A. Treiber, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients

S. Krähenbühl, A. Halabi, H. Chadha‐Boreham, 2006, Clinical pharmacology and therapeutics.

First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal test.

L. Heinemann, K. Rave, J. Dingemanse, 2010, Diabetes technology & therapeutics.

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects

D. Csonka, S. Grill, P. Sidharta, 2020, British journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple‐dose study in healthy subjects

J. Dingemanse, P. Sidharta, P. V. van Giersbergen, 2013, Journal of clinical pharmacology.

Single‐ and multiple‐dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects

Z. Diamant, J. Dingemanse, P. Sidharta, 2014, Fundamental & clinical pharmacology.

Setipiprant, a selective CRTH2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics

M. Silkey, B. O'connor, B. Leaker, 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects

J. Dingemanse, P. Sidharta, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment

J. Dingemanse, P. Sidharta, I. Ulč, 2019, Clinical Drug Investigation.

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

J. Dingemanse, P. Sidharta, M. Kankam, 2019, Drug design, development and therapy.

Assessment of Peripheral Serotonin Synthesis Using Stable Isotope‐Labeled Tryptophan

P. Groenen, J. Dingemanse, R. Welford, 2018, Clinical pharmacology and therapeutics.

Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus

P. Sidharta, 2015 .

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

J. Dingemanse, P. Sidharta, P. V. van Giersbergen, 2018, Pharmacology.

Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

J. Dingemanse, P. Sidharta, P. Giersbergen, 2009, Journal of clinical pharmacology.

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects

M. Fontes, J. Dingemanse, P. Sidharta, 2020, Clinical pharmacology in drug development.

Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT‐774312: A novel CRTH2 antagonist

J. Dingemanse, P. Sidharta, D. Lott, 2019, Basic & clinical pharmacology & toxicology.

A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects

J. Zisowsky, P. Groenen, J. Dingemanse, 2015, Journal of clinical pharmacology.

Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects

J. Dingemanse, P. Sidharta, N. Hurst, 2016, Journal of clinical pharmacology.

Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection

J. Zisowsky, P. Groenen, J. Dingemanse, 2016, Clinical Pharmacokinetics.

Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects

J. Dingemanse, P. Sidharta, M. Issac, 2017, Journal of clinical pharmacology.

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment

J. Dingemanse, P. Sidharta, P. Giersbergen, 2012 .

Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects

J. Dingemanse, P. Sidharta, H. Dietrich, 2012 .

Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects

M. Wolzt, J. Dingemanse, P. Sidharta, 2012, ATS 2012.

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

A. Halabi, J. Dingemanse, P. Sidharta, 2011, European Journal of Clinical Pharmacology.

Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis

J. Dingemanse, P. Sidharta, M. Géhin, 2016, Pharmacology.

Development of a decision-making biomarker for CRTH2 antagonism in clinical studies

J. Zisowsky, P. Groenen, M. Holdener, 2015 .

Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans.

H. E. Meyer zu Schwabedissen, J. Dingemanse, P. Sidharta, 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders

J. Dingemanse, R. Welford, P. Sidharta, 2020, Clinical and translational science.

Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers

D. Csonka, P. Sidharta, R. Štěpánová, 2020, Pharmacology research & perspectives.

Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.

J. Dingemanse, P. Sidharta, H. M. Z. zu Schwabedissen, 2020, Pharmacological research.

Population Pharmacodynamic Modeling of Hyperglycemic Clamp and Meal Tolerance Tests in Patients with Type 2 Diabetes Mellitus

D. Mager, J. Dingemanse, P. Sidharta, 2013, The AAPS Journal.

Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

L. Heinemann, S. Krähenbühl, K. Rave, 2009, British journal of clinical pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan

A. Treiber, J. Dingemanse, P. Sidharta, 2015, Clinical Pharmacokinetics.

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

A. Treiber, J. Dingemanse, P. Sidharta, 2011, The AAPS Journal.

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet

M. Burnier, M. Maillard, G. Wuerzner, 2020, Clinical pharmacology and therapeutics.

Macitentan Does Not Interfere with Hepatic Bile Salt Transport

R. de Kanter, A. Treiber, P. Sidharta, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.

J. Dingemanse, P. Sidharta, H. Fischer, 2021, Current drug metabolism.

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

A. Halabi, M. Fontes, J. Dingemanse, 2022, Scientific Reports.

Effects of Multiple‐Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin

J. Dingemanse, P. Sidharta, 2020, Clinical pharmacology in drug development.

Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.

J. Dingemanse, P. Sidharta, Kathrin Reseski, 2014, Pulmonary pharmacology & therapeutics.

Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist

A. Halabi, A. Treiber, J. Dingemanse, 2014, European Journal of Clinical Pharmacology.

Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects

J. Dingemanse, P. Sidharta, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist

J. Dingemanse, P. Sidharta, G. Sabattini, 2021, British journal of clinical pharmacology.

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

J. Dingemanse, P. Sidharta, I. Ulč, 2014, Journal of clinical pharmacology.

Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.

J. Dingemanse, P. Sidharta, A. Krause, 2024, Journal of pharmacokinetics and pharmacodynamics.